Oppenheimer Initiates Coverage on TriSalus Life Sciences (NASDAQ:TLSI)

Oppenheimer started coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a report released on Monday morning, MarketBeat reports. The brokerage issued an outperform rating and a $10.00 price target on the stock.

A number of other equities research analysts have also recently commented on the company. Canaccord Genuity Group reaffirmed a buy rating and set a $12.00 price objective on shares of TriSalus Life Sciences in a research note on Thursday, June 27th. Canaccord Genuity Group assumed coverage on shares of TriSalus Life Sciences in a report on Thursday, May 30th. They issued a buy rating and a $12.00 price target for the company.

TriSalus Life Sciences Price Performance

Shares of TLSI opened at $4.62 on Monday. The business’s 50 day simple moving average is $5.44 and its 200-day simple moving average is $7.37. TriSalus Life Sciences has a one year low of $3.32 and a one year high of $10.42.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.21) earnings per share for the quarter. The business had revenue of $7.36 million for the quarter.

Insider Transactions at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela purchased 7,520 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were acquired at an average cost of $5.20 per share, with a total value of $39,104.00. Following the completion of the transaction, the chief executive officer now owns 377,382 shares in the company, valued at $1,962,386.40. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 76.20% of the stock is owned by corporate insiders.

Institutional Trading of TriSalus Life Sciences

Several large investors have recently bought and sold shares of the business. Wolverine Asset Management LLC bought a new stake in shares of TriSalus Life Sciences during the 2nd quarter valued at approximately $240,000. Highbridge Capital Management LLC acquired a new position in shares of TriSalus Life Sciences in the second quarter valued at approximately $1,184,000. Finally, Duquesne Family Office LLC raised its holdings in TriSalus Life Sciences by 35.1% in the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after buying an additional 110,966 shares during the last quarter. 2.58% of the stock is owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.